A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease

Trial Profile

A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2018

At a glance

  • Drugs BAN 2401 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Eisai Inc
  • Most Recent Events

    • 21 Dec 2017 According to an Eisai Co Ltd media release, a comprehensive final analysis of this trial will be conducted at 18 months. The results of the final analysis are expected during the second half of 2018.
    • 21 Dec 2017 According to an Eisai Co Ltd media release, an Independent Data Monitoring Committee has determined that BAN2401 did not meet the criteria for success based on a Bayesian analysis at 12 months as the primary endpoint in this trial and the blinded study will continue as per protocol.
    • 18 Sep 2017 Planned End Date changed from 1 Sep 2018 to 1 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top